Company Profile
Idera Stock Price, News & Analysis
- Ticker:
- IDRA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for IDRA.
Company overview
Business overview
Idera Pharmaceuticals is a historical small-cap biotechnology name associated with immunology and oncology programs, including work around innate immune pathways. The company has long been a legacy example of a narrow pipeline trying to create value in a very competitive biotech market.
Geographic Base and Sector Classification
Idera is headquartered in the United States and listed on NASDAQ, with a profile that has historically sat in small-cap biotech. It belongs more to the legacy development group than to a large commercial franchise.
Business Model Characteristics
The business model was defined by clinical development, capital preservation, and the ability to keep a focused pipeline alive long enough to generate value. Investors historically watched data updates, restructuring activity, and financing runway.
Position Within the Biotechnology Landscape
Idera sits in the historical category of high-risk micro-cap biotech names. It is best understood as a legacy development story where execution and financing risk were always dominant.
Future catalysts
Idera is now largely a legacy / closeout story, so the catalysts are any asset-resolution update rather than a live pipeline readout. The company is mainly in wind-down mode.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Idera do?
Idera Pharmaceuticals is a historical small-cap biotechnology name associated with immunology and oncology programs, including work around innate immune pathways. The company has long been a legacy example of a narrow pipeline trying to create value in a very competitive biotech market.
On which exchange is IDRA stock listed?
Idera (IDRA) is associated with NASDAQ, United States, Biopharma.
What is Idera?
Idera is now largely a legacy / closeout story, so the catalysts are any asset-resolution update rather than a live pipeline readout.
Which conditions is Idera targeting with Idera?
Idera is associated with oncology, immunology based on its company overview and current catalyst commentary.
How does Idera describe recent progress with Idera?
Idera is now largely a legacy / closeout story, so the catalysts are any asset-resolution update rather than a live pipeline readout.
What is Pharmaceuticals?
Idera Pharmaceuticals is a historical small-cap biotechnology name associated with immunology and oncology programs, including work around innate immune pathways.
What should investors watch for with Pharmaceuticals?
Idera is now largely a legacy / closeout story, so the catalysts are any asset-resolution update rather than a live pipeline readout. The company is mainly in wind-down mode.
What future catalysts are investors watching for Idera?
Idera is now largely a legacy / closeout story, so the catalysts are any asset-resolution update rather than a live pipeline readout. The company is mainly in wind-down mode.